International journal of biological macromolecules

Indian journal of pediatrics

Vaccine

[1] Diversity of sialidases found in the human body - A review.

[2] Influenza.

[3] Pharmacists' impact on older adults' access to vaccines in the United States.

[4] influenza virus segment composition influences viral stability in the environment

[5] current approaches for diagnosis of influenza virus infections in humans

[6] characterisation of enzymatic activities of h5n1 influenza virus

[7] Molecular modeling studies demonstrate key mutations that could affect the ligand recognition by influenza AH1N1 neuraminidase

[8] Influenza treatment and prophylaxis with neuraminidase inhibitors: a review

[9] Influenza treatment and prophylaxis with neuraminidase inhibitors: a review

[10] Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.

[11] Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity

[12] Pre-existing Antineuraminidase Antibodies Are Associated With Shortened Duration of Influenza A(H1N1)pdm Virus Shedding and Illness in Naturally Infected Adults

[13] mutation analysis of the neuraminidase gene of influenza a(h1n1)pdm09 in tunisia between 2009 and 2017 seasons

[14] dual acting neuraminidase inhibitors open new opportunities to disrupt the lethal synergism between streptococcus pneumoniae and influenza virus

[15] neuraminidase 1 activates insulin receptor and reverses insulin resistance in obese mice

[16] anti-tumor effects of an oncolytic adenovirus expressing hemagglutinin-neuraminidase of newcastle disease virus in vitro and in vivo

[17] Design, synthesis and biological evaluation of honokiol derivatives as influenza neuraminidase inhibitors.

[18] Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants

[19] Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons

[20] Treatment of influenza with neuraminidase inhibitors: virological implications

[21] Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen

[22] Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods

[23] Molecular modeling studies demonstrate key mutations that could affect the ligand recognition by influenza AH1N1 neuraminidase

[24] Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitor resistance